Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Louis A. VanderMolen"'
Autor:
Khosrow Mahdavi, Robert O. Dillman, Louis A. VanderMolen, Neil M. Barth, Stephanie E. McClure
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 27:337-343
For more than 20 years interleukin-2 (IL2) was the preferred treatment for medically fit metastatic melanoma patients, but recently two new agents, ipilimumab and vemurafenib, were approved for stage IV disease. Single-institution data were used to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b6610afd95190f03b3c23bb572214b
https://doi.org/10.1089/cbr.2012.1220
https://doi.org/10.1089/cbr.2012.1220
Autor:
Warren H. Fong, Louis A. VanderMolen, Robert O. Dillman, Khosrow Mahdavi, Neil M. Barth, Stephanie E. McClure
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 26:273-277
Interleukin-2 (IL-2) was the preferred treatment for medically fit patients with advanced kidney cancer, but recently, several targeted therapies have been approved for metastatic renal cell carcinoma. We wished to determine the long-term survival ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f356db21eba6f04b5ae38e27e331d33
https://doi.org/10.1089/cbr.2011.0969
https://doi.org/10.1089/cbr.2011.0969
Autor:
Robert O. Dillman, Louis A. VanderMolen, Kanoe Allen, Neil M. Barth, Linda D. Beutel, Sherri Chico
Publikováno v:
American Journal of Clinical Oncology. 28:281-288
During 1990-1999, we treated 60 patients with breast cancer who had distant metastases with high-dose chemotherapy and autologous stem cell rescue (HDC) after they had responded to induction chemotherapy. HDC regimens were MiTepa (60 mg/m2 mitoxantro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee957b6e46c1100980f0fde9571ab29
https://doi.org/10.1097/01.coc.0000156917.43490.65
https://doi.org/10.1097/01.coc.0000156917.43490.65
Autor:
Linda D. Beutel, Louis A. VanderMolen, Robert O. Dillman, Cristina de Leon, Carol DePriest, Neil M. Barth, Khosrow Mahdavi, Shankar K. Nayak
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 19:570-580
We previously reported the laboratory methodology for producing patient-specific irradiated autologous tumor-cell products derived from short-term cultured tumor cells from resected renal cell carcinoma, and described preliminary clinical results. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54116ca724f0fac38b5ffaf985b08981
https://doi.org/10.1089/cbr.2004.19.570
https://doi.org/10.1089/cbr.2004.19.570
Autor:
Louis A. VanderMolen, Audrey A. O'Connor, Robert O. Dillman, Neil M. Barth, David H. Garfield, Shankar K. Nayak, Khosrow Mahdavi, Cristina de Leon
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 16:47-54
We established short-term cultures of autologous tumors from patients with renal carcinoma for use as active specific immunotherapy (i.e., autologous vaccine).Between 9/91 and 9/99 the cell biology laboratory of the Hoag Cancer Center received 69 kid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::100ddcb3517e0eb4196b38ff65a7c885
https://doi.org/10.1089/108497801750096023
https://doi.org/10.1089/108497801750096023
Autor:
Kevin C. Conlon, Louis A. VanderMolen, Dan L. Longo, John E. Janik, William C. Kopp, Ronald G. Steis, John W. Smith, M Sznol, Robert G. Fenton, Jon Holmlund, William Sharfman, S P Creekmore, Barry L. Gause, W J Urba
Publikováno v:
Journal of Clinical Oncology. 14:2234-2241
PURPOSE Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the setting of significant toxicity. The purpose of this study is to define the maximum-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f047f45ba7103730d691c23933d6c1
https://doi.org/10.1200/jco.1996.14.8.2234
https://doi.org/10.1200/jco.1996.14.8.2234
Autor:
Audrey A. O'Connor, Linda Simpson, Louis A. VanderMolen, Peter Vanderplas, Robert O. Dillman, Neil M. Barth
Publikováno v:
American journal of clinical oncology. 26(2)
Pharmacy logbooks and clinical trial records were used to identify all 60 patients with metastatic melanoma who were treated as inpatients with intermediate-dose, continuous-infusion interleukin-2 (IL-2) in Hoag Hospital during 1987 to 1998. The hosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3de09353834944526286b232672a518b
https://pubmed.ncbi.nlm.nih.gov/12714884
https://pubmed.ncbi.nlm.nih.gov/12714884
Publikováno v:
Cancer investigation. 20(2)
Urethral cancers are uncommon cancers that present difficult management problems because penectomy has been the standard treatment for curative intent for all but small distal, low-grade lesions. W...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ef4e4aee4b729d073d11fc0b0c4387
https://pubmed.ncbi.nlm.nih.gov/11901541
https://pubmed.ncbi.nlm.nih.gov/11901541
Autor:
Carol DePriest, C. Church, Martin J. Bury, Louis A. VanderMolen, Robert O. Dillman, Michael C. Wiemann
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 12(4)
Interleukin-2 (IL-2) is an active agent for the treatment of melanoma. In animal studies, polyethylene glycol conjugated (PEG) IL-2 was found to be effective in certain IL-2-resistant models. Bolus/infusional IL-2 administered to approximate the phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::770b7c2653c4262933d4aadc58e3b59d
https://pubmed.ncbi.nlm.nih.gov/10851472
https://pubmed.ncbi.nlm.nih.gov/10851472
Autor:
Audrey A. O'Connor, Robert O. Dillman, Louis A. VanderMolen, Khosrow Mahdavi, Neil M. Barth, Shankar K. Nayak
Publikováno v:
Cancer biotherapy. 10(1)
Perhaps the best example of the integration of chemotherapy and biotherapy is autologous stem cell rescue following high dose chemotherapy. This analysis was undertaken to determine the outcome for patients treated in an autologous bone marrow transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42cef56452840d7db3ec9bfdd6a85ff
https://pubmed.ncbi.nlm.nih.gov/7780484
https://pubmed.ncbi.nlm.nih.gov/7780484